| Autor: |
Benotmane, Ilies, Jungbauer-Groznica, Martin, Staropoli, Isabelle, Planas, Delphine, Dehan, Océane, Brisebarre, Angela, Simon-Loriere, Etienne, Fafi-Kremer, Samira, Schwartz, Olivier, Bruel, Timothée, Caillard, Sophie |
| Předmět: |
|
| Zdroj: |
Transplant International; 2024, p1-4, 4p |
| Abstrakt: |
This article examines the effectiveness of monoclonal antibodies (mAbs) in neutralizing SARS-CoV-2 variants in kidney transplant recipients. The study found that certain mAbs had low levels of neutralizing activity against specific variants, but in vivo neutralization showed slightly increased activity after administration. The article suggests that even though these variants are no longer circulating, there is still residual antiviral activity. The study also discusses the potential benefits of increasing the dosage of mAbs to enhance their efficacy against COVID-19 variants. However, the study has limitations, and further research is needed to better understand antibody activity and optimize patient care. Funding for the research was received from various sources, and some authors have declared potential conflicts of interest. [Extracted from the article] |
| Databáze: |
Complementary Index |
| Externí odkaz: |
|
